LitAlert ~~ GeneLit.com

Nanoparticle-Mediated PRDX2 Inhibition for Specific Targeting of CHK2-Null Colorectal Cancer.
Ahmad A, Prakash R, Khan MS, Altwaijry N, Asghar MN, Raza SS, Khan R.
ACS Biomater Sci Eng. 2022 Nov 29. doi: 10.1021/acsbiomaterials.2c01073. Epub ahead of print.

3D CRISPR screen in prostate cancer cells reveals PARP inhibitor sensitization through TBL1XR1-SMC3 interaction.
Zhang H, Gao H, Gu Y, John A, Wei L, Minhong Huang M, Yu J, Adeosun AA, Weinshilboum RM, Wang L.
Front Oncol. 2022 Nov 29;12:999302. doi: 10.3389/fonc.2022.999302.

Clinical and psychological implications of secondary and incidental findings in cancer susceptibility genes after exome sequencing in patients with rare disorders.
Carrasco E, López-Fernández A, Codina-Sola M, Valenzuela I, Cueto-González AM, Villacampa G, Navarro V, Torres-Esquius S, Palau D, Cruellas M, Torres M, Perez-Dueñas B, Abulí A, Diez O, Sábado-Álvarez C, García-Arumí E, Tizzano EF, Moreno L, Balmaña J.
J Med Genet. 2022 Nov 29:jmg-2022-108929. doi: 10.1136/jmg-2022-108929. Epub ahead of print.

Using Genomic Variation to Distinguish Ovarian High-Grade Serous Carcinoma from Benign Fallopian Tubes.
Gonzalez-Bosquet J, Cardillo ND, Reyes HD, Smith BJ, Leslie KK, Bender DP, Goodheart MJ, ,Devor EJ.
Int J Mol Sci. 2022 Nov 26;23(23):14814. doi: 10.3390/ijms232314814.

Investigation of mRNA Expression Levels of Tip60 and Related DNA Repair Genes in Molecular Subtypes of Breast Cancer.
Miser-Salihoglu E, Demokan S, Karanlik H, Karahalil B, Önder S, Cömert S, Yardim-Akaydin S.
Clin Breast Cancer. 2022 Nov 12:S1526-8209(22)00235-X. doi: 10.1016/j.clbc.2022.10.012. Epub ahead of print.